REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1595463
A review of the participation of DDIT4 in the tumor immune microenvironment through inhibiting PI3K-Akt/mTOR pathway
Provisionally accepted
- 1Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, China
- 2Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
DDIT4 (DNA Damage Inducible Transcript 4), a well-established inhibitor of the PI3K-Akt/mTOR pathway, is upregulated under cellular stress conditions. Extensive research has demonstrated that DDIT4 expression is aberrantly elevated in various malignancies, where it exhibits context-dependent roles in either tumor promotion or suppression. However, the mechanisms underlying how DDIT4 is involved in tumor immune regulation remain to be fully elucidated. This review systematically summarizes the multifaceted mechanisms by which DDIT4 participates in tumor immunomodulation, primarily through its inhibition of the PI3K-Akt/mTOR pathway to induce autophagy activation and metabolic reprogramming; furthermore, it comprehensively examines DDIT4's regulatory effects on various components within the tumor immune microenvironment, including tumor cells, both innate and adaptive immune cells, and immunomodulatory cytokines. This comprehensive analysis aims to establish a theoretical foundation for considering DDIT4 as a potential therapeutic target in tumor immunotherapy.
Keywords: DDIT4, mTORC1, Tumor immune microenvironment, Autophagy, PI3K-AKT/mTOR pathway
Received: 18 Mar 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 焦 and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yang Xiang, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.